Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876357 | 0.93 | CYP2E1 (0.42) | MKNK1CYP2E1KDM4EHTTATM | |
| Hydrochloric Acid SCHEMBL2874873 | 0.92 | CYP2E1 (0.41) | MKNK1CYP2E1KDM4EHTTATM | |
| SCHEMBL2870751 | 0.89 | KDM4E (0.47) | MKNK1KDM4EHTTATM | |
| SCHEMBL14048987 | 0.88 | OPRD1 (0.42) | MKNK1KDM4EIKBKBCHEK1OPRD1 | |
| SCHEMBL2878936 | 0.86 | MKNK1 (0.38) | MKNK1KDM4EHTTATMUSP30 | |
| SCHEMBL14030873 | 0.86 | SMN1; SMN2 (0.43) | HTT | |
| SCHEMBL2157834 | 0.84 | CYP2E1 (0.43) | CYP2E1KDM4EHTTATMUSP30 | |
| SCHEMBL2877042 | 0.84 | NR1I2 (0.41) | CYP2E1KDM4EHTTATMCHEK1 | |
| Hydrochloric Acid SCHEMBL2878280 | 0.83 | NR1I2 (0.41) | CYP2E1KDM4EHTTATMCHEK1 | |
| SCHEMBL2876967 | 0.81 | KDM4E (0.46) | KDM4EHTTATMCHEK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | MKNK1 3192/4885CYP2E1 202/4885KDM4E 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.